Keurig Dr Pepper vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Burlington MA beverages (NASDAQ: KDP) at $15.35B FY2024 revenue (+3.6%); Dr Pepper/7UP/Snapple + Keurig K-Cup, 82% FCF growth, 2025 guidance mid-single-digit growth competing with Coca-Cola and PepsiCo.
About
Keurig Dr Pepper Inc. is a Burlington, Massachusetts-based beverage company — publicly traded on NASDAQ (NASDAQ: KDP) as an S&P 500 Consumer Staples component — manufacturing, marketing, and distributing hot beverages (coffee through the Keurig single-serve system and Green Mountain roasted coffee brands), cold beverages (Dr Pepper, 7UP, Snapple, Canada Dry, A&W, Sunkist, Bai, Core, Clamato, Mott's, Hawaiian Punch, Penafiel), and producing/selling the Keurig K-Cup system (over 500 varieties of licensed K-Cup pods from 75+ coffee brands) through approximately 27,000 employees. In fiscal year 2024, Keurig Dr Pepper reported revenue of $15.35 billion (+3.6% year-over-year), adjusted diluted EPS growth of 8%, operating cash flow growth of 67% to $2.2 billion, and free cash flow growth of 82% to $1.7 billion. For 2025, KDP guided mid-single-digit net sales growth and high-single-digit adjusted EPS growth, reflecting continued volume growth in both the cold beverages portfolio and Keurig brewer and pod sales recovery. CEO Tim Cofer, who joined from Mondelez International in 2023, has prioritized revenue management (balancing price and volume), operational efficiency, and brand investment across KDP's portfolio of over 125 owned, licensed, and partner brands. Keurig Dr Pepper was formed through the 2018 merger of Keurig Green Mountain (coffee systems) and Dr Pepper Snapple Group (beverages), controlled by JAB Holding Company (a Luxembourg-based holding company of the Reimann family).
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.